Species differences in the distribution of central 5-HT1 binding sites: a comparative autoradiographic study between rat and guinea pig

In this study, we compared the localization of central 5-HT₁ binding sites of rat and guinea pig. The 5-HT_1B sites were absent in the guinea pig brain. Good correlations were found between species in the regional distribution of 5-HT₁ sites labelled with [³H]5-HT(r = 0.73), 5-HT_1A sites labelled with [³H]8-OH-DPAT (r = 0.87), and 5-HT_1B versus 5-HT_1D sites labelled with [³H]5-HT in the presence of ipsapirone and DOI (r = 0.76). Despite the overall similarities, species differences were observed in many brain regions. The CA1/CA2 fields of the hippocampus and the dorsal subiculum displayed significantly more 5-HT_1A receptor binding in guinea pig than in rat. Conversely, the 5-HT_1A binding in dorsolateral septum, cingulate cortex and laminae IV-V of the neocortex, was more pronounced in rat. Areas almost exclusively containing 5-HT_1B or 5-HT_1D sites, such as the ventral pallidum, globus pallidus and substantia nigra, expressed markedly more [³H]5-HT binding in rat as compared to guinea pig, while the opposite occurred in claustrum, dorsal endopiriform nucleus, lateral geniculate nucleus, and superficial grey layer of the superior colliculus. The implications of the species differences are illustrated by the binding of [³H]eltoprazine. The distribution of [³H]eltoprazine binding sites showed a good correlation with that of the 5-HT_1B sites in rat (r = 0.89), and with that of the 5-HT_1A sites in guinea pig (r = 0.97). The data give rise to the possibility that differences in the presence and distribution of 5-HT₁ receptor sites are related to species differences in behavioral, neurochemical and physiological responses to drugs with 5-HT₁ receptor affinity.     

Two distinct serotonin receptors: regional variations in receptor binding in mammalian brain

Two distinct serotonin receptors in mammalian brain are labeled respectively with [³H]serotonin (5-HT₁) and [³H]spiperone (5-HT₂). In general, agonists display highest affinities for 5-HT₁ while antagonists prefer 5-HT₂ sites. To conduct regional studies of 5-HT receptors, we estimated 5-HT₂ sites with [³H]spiperone, using the 5-HT₂ specific antagonist cinanserin to displace binding to 5-HT₂ but not dopamine receptors and sulpiride to displace [³H]spiperone from dopamine but not 5-HT receptors. About 15% of cerebral cortical [³H]spiperone binding appears to involve dopamine sites and the remainder involves 5-HT₂ receptors. In the corpus striatum about 80% of [³H]spiperone binding labels dopamine receptors and the rest involves 5-HT₂ sites. [³H]mianserin binds about equally to 5-HT₂ sites are studies selectively by displacing histamine H₁-receptor binding with the H₁-antihistamine triprolidine. [³H]LSD labels both 5-HT₁ and 5-HT₂ receptors. Its binding to 5-HT₁ sites is displaced selectively with 5-HT, while its binding to 5-HT₂ receptors is displaced with cinanserin. [³H]5-HT labels only 5-HT₁ receptors. The regional distribution of the two 5-HT receptors is similar in rat, guinea pig and bovine brain. However, the regional patterns of 5-HT₁ and 5-HT₂ receptors differ considerably in all 3 species. The hippocampus is quite high in 5-HT₁ receptors but low in 5-HT₂ sites. The cerebellum contains the lowest levels of both 5-HT₁ and 5-HT₂ receptors. In bovine brain, most areas contain similar numbers of 5-HT₁ and 5-HT₂ receptors. However, the substantia nigra, the richest 5-HT₁ area inbovine brain, possesses 10 times more 5-HT₁ than 5-HT₂ sites.     

Cortical and striatal variations in drug competition studies with putative 5-hydroxytryptamine1D binding sites

The ability of 5-hydroxytryptamine (5-HT), 5-car☐ytryptamine (5-CT) and sumatriptan to compete for [³H]5-HT binding sites in various brain tissues was analyzed in bovine, guinea pig, pig and human cortex and caudate. Radioligand binding conditions were designed to allow for the selective labeling of putative 5-HT_1D binding sites. 5-HT competed monophasically with putative 5-HT_1D binding sites in each of the 8 tissues studied. By contrast, both 5-CT and sumatriptan,competed with markedly shallow displacement curves in each of the 8 tissues. In the case of sumatriptan, complete displacement of [³H]5-HT could not be achieved even at concentrations as high as 2000 times its IC₅₀ value. These data indicate that 10⁻⁵ M 5-HT should not be used to define specific binding to 5-HT_1D receptors in radioligand binding assays. Instead, 5-HT_1D receptor binding sites should be redefined as [³H]5-HT-labeled binding sites displaced by 10⁻⁵ M sumatriptan.     

Quantitative autoradiography of 5-HT1D and 5-HT1E binding sites labelled by [H]5-HT, in frontal cortex and the hippocampal region of the human brain

In human cortex and hippocampus area, [³H]5-HT (5 nM) labels 5-HT_1A, 5-HT_1D and 5-HT_1E sites. After masking 5-HT_1A receptors by 0.1 μM 8-OH-DPAT, the binding displaced by 0.1 μM 5-CT presumably represented 5-HT_1D sites and the remaining binding 5-HT_1E sites. In frontal cortex, 5-HT_1A receptors represented the main binding in layers II and VI and a lower fraction on other layers. 5-HT_1D and 5-HT_1E sites, were more homogeneously distributed in layers II to VI (21–34% of specific [³H]5-HT binding). 5-HT_1E sites were of similar affinities (K_D close to 6–8 nM) in the cortical layers II to VI. In CA1 field of hippocampus, (pyramidal layer, stratum radiatum, molecular layer), CA2 and dentate gyrus, 5-HT_1A receptors represented the major fraction, 5-HT_1D sites a significant fraction and 5-HT_1E a minor fraction of the specific [³H]5-HT binding. In CA3–CA4 fields, 5-HT_1A receptors were less densely present, 5-HT_1D sites were predominant and 5-HT_1E sites represented a significant fraction (27%). The highest densities of 5-HT_1E sites have been measured in subiculum, where 5-HT_1A, 5-HT_1D, and 5-HT_1E binding sites were equally represented and in entorhinal cortex where 5-HT_1E sites represented the major binding in layer III. They were also present in layers II and IV (29 and 24%) and, to a lesser extent, in layers V and VI. 5-HT_1A sites were predominant in layer VI, II and V and were less abundant in other layers. 5-HT_1D were homogeneously present in layers II, III, IV and were present in low amounts in other layers. No 5-HT_1E were detected in choroid plexus, where [³H]5-HT was dramatically reduced by mesulergine (5-HT_2C receptors). No significant displacement of [³H]5-HT by mesulergine was measured in other structures.     

Differential radioligand binding properties of [H]5-hydroxytryptamine and [H]mesulergine in a clonal 5-hydroxytryptamine1C cell line

[³H]5-Hydroxytryptamine ([³H]5-HT) and [³H]mesulergine were used to label 5-HT_1C receptors expressed in NIH 3T3 mouse fibroblast cells. Using a rapid filtration assay, saturation analysis of the [³H]5-HT radioligand data indicate that the binding is biphasic. Based on computerized analysis of the data, a 2-site model of radioligand binding is significantly more consistent with the data than a one-site model (P < 0.01). The K_D values of [³H]5-HT for the 2 populations are0.5±0.1nM and31±15nM, while the B_max values are400±90pmol/g protein and 3,000±600 pmol/g protein, respectively. A biphasic binding pattern is also observed with [³H]5-HT using a centrifugation assay (K_D1 = 0.6±0.06nM, K_D2 = 60±10nM;B_max1 = 740±90pmol/g, B_max2 = 4,000±700pmol/g). By contrast, saturation analysis of [³H]mesulergine binding is monophasic (K_D = 4.7±0.7nM) with a B_max value (6,800±1,000pmol/g protein) that is significantly greater than that obtained using [³H]5-HT (P < 0.01). Drug competition studies confirm that both [³H]5-HT and [³H]mesulergine label at least 2 subpopulations of expressed 5-HT_1C receptors in NIH 3T3 cells. 10⁻⁴ M GTP eliminates the high affinity [³H]5-HT-labeled binding sites with minimal effect on the low affinity [³H]5-HT-labeled sites and no effect on [³H]mesulergine-labeled sites. These data demonstrate that at least 2 distinct subpopulations of 5-HT_1C receptors in NIH 3T3 cells can be differentiated using radioligand binding techniques.     

Characterization and quantitative autoradiography of [H]tryptamine binding sites in rat brain

[³H]tryptamine binds with high affinity (K_d = 9.1nM, B_max= 54fmol/mg wet wt.) to tissue sections of rat brain. The binding occurs rapidly and is reversible. Low concentrations of the β-carbolines harmaline (IC₅₀ = 25nM) and tetrahydronorharman (tetrahydro-β-carboline), IC₅₀ = 50nM) inhibit [³H]tryptamine binding. Serotonin (5-HT, IC₅₀ = 2600nM) as well as the 5-HT receptor antagonists methysergide and metergoline displace [³H]tryptamine at much higher concentrations from brain slices. The distribution of [³H]tryptamine binding sites in section of rat brain has been analyzed by quantitative autoradiography. The highest density of binding sites is found in the nucleus (n.) interpreduncularis, a slightly lower one in the locus coeruleus. Moderately labelled are the n. accumbens septi, n. septi lateralis, n. medalis habenulae, n. tractus olfactorii lateralis, the central region of the amydgala, n. caudatsu/putamen, n. reuniens and the hippocampal formation. A low density of binding sites is detected in the cerebral cortex and the subiculum. Even less binding sites are found in the n. dorsalis raphe and the substantia nigra. The pattern of distribution of [³H]tryptamine binding sites differs from that of [³H]5-HT(5-HT₁), [³H]ketanserin (5-HT₂) as well as [³H]imipramine binding sites. These data suggest unique tryptamine binding sites.     

Selective loss of serotonin recognition sites in the parietal cortex in Alzheimer's disease

Numbers of serotonin (5-HT) recognition sites of total 5-HT₁, 5-HT_1A and 5-HT₂ subtypes have been measured in frontal, temporal and parietal cortex from human brain postmortem, using binding of [³H] 5-hydroxytryptamine (5-HT), [³H] 8-hydroxy-2-(di-n-propylamino) tetralin and [³H] ketanserin, respectively. A comparison has been made between 11 patients with Alzheimer's disease (AD) and 20 matched controls. Significant disease-related differences were observed only in the parietal cortex for total 5-HT₁ and 5-HT₂ recognition sites. Age-related decrease in numbers of 5-HT₂ recognition sites was seen in the controls, whereas an age-related increase in the numbers of the same site was seen in AD patients. These changes are discussed in relation to disease severity and cortical nerve cell loss in ageing and AD.     

Plastic responses of neonatal 5-hydroxytryptamine1B receptors to 5,7-dihydroxytryptamine lesions mapped by quantitative autoradiography

We previously found different effects on behavior, serotonin (5-HT) concentrations, 5-HT uptake sites, and 5-HT_1A binding sites of neonatal 5,7-dihydroxytryptamine (5,7-DHT) lesions depending on the route of 5,7-DHT injection. To study the impact of early lesions on 5-HT_1B sites as putative 5-HT terminal autoreceptors, we labelled them autoradiographically with [³H]5-HT 4 months after intraperitoneal (i.p.) or intracisternal (i.c.) 5,7-DHT injection during the first postnatal week and quantitated specific binding in 22 brain regions. Changes were confined to the subiculum and substantia nigra, regions with the most 5-HT_1B-specific binding and projection areas of structures with high mRNA expression. Both routes of 5,7-DHT injection were associated with increases in specific binding in subiculum (24% for i.p. and 47% for i.c. route). In contrast, there was a 32% increase in specific binding in the substantia nigra in rats with lesions made i.c. but not i.p. No significant differences were found in nucleus accumbens, caudate-putamen or other brain areas. In saturation homogenate binding studies of 5-HT_1B sites using [¹²⁵I]iodocyanopindolol 1 month after i.p. injections, neonatal 5,7-DHT lesions did not significantly alter B_max or K_d in the neocortex, striatum, diencephalon or brainstem. These data indicate the differential effects of the route of neonatal 5,7-DHT injections on plasticity of 5-HT_1B receptor recognition sites and suggest the presence of a subpopulation of post-synaptically located 5-HT_1B sites which increases in response to denervation. The data also suggest that sprouting of 5-HT neurons after neonatal 5,7-DHT lesions does not involve 5-HT_1B sites.     

Increased binding at 5-HT1A, 5-HT1B, and 5-HT2A receptors and 5-HT transporters in diet-induced obese rats

5-Hydroxytryptamine (5-HT, serotonin), synthesized in midbrain raphe nuclei and released in various hypothalamic sites, decreases food intake but the specific 5-HT receptor subtypes involved are controversial. Here, we have studied changes in the regional density of binding to 5-HT receptors and transporters and the levels of tryptophan hydroxylase, in rats with obesity induced by feeding a palatable high-energy diet for 7 weeks. We mapped binding at 5-HT receptor subtypes and transporters using quantitative autoradiography and determined tryptophan hydroxylase protein levels by Western blotting. In diet-induced obese (DiO) rats, specific binding to 5-HT_1A receptors ([³H]8-OH-DPAT) was significantly increased in the dorsal and median raphe by 90% (P<0.01) and 132% (P<0.05), respectively, compared with chow-fed controls. 5-HT_1B receptor binding sites ([¹²⁵I]cyanopindolol) were significantly increased in the hypothalamic arcuate nucleus (ARC) of DiO rats (58%; P<0.05), as were 5-HT_2A receptor binding sites ([³H]ketanserin) in both the ARC (44%; P<0.05) and lateral hypothalamic area (LHA) (121%; P<0.05). However, binding to 5-HT_2C receptors ([³H]mesulgergine) in DiO rats was not significantly different from that in controls in any hypothalamic region. Binding to 5-HT transporters ([³H]paroxetine) was significantly increased (P<0.05) in both dorsal and median raphe, paraventricular nuclei (PVN), ventromedial nuclei (VMH), anterior hypothalamic area (AHA) and LHA of DiO rats, by 47%–165%. Tryptophan hydroxylase protein levels in the raphe nuclei were not significantly different between controls and DiO rats. In conclusion, we have demonstrated regionally specific changes in binding to certain 5-HT receptor subtypes in obesity induced by voluntary overeating of a palatable diet. Overall, these changes are consistent with reduced 5-HT release and decreased activity of the 5-HT neurons. Reduction in the hypophagic action of 5-HT, possibly acting at 5-HT_1A, 5-HT_1B and 5-HT_2A receptors, may contribute to increased appetite in rats presented with highly palatable diet.     

Density and Distribution of Hippocampal Neurotransmitter Receptors in Autism: An Autoradiographic Study

Neuropathological studies in autistic brains have shown small neuronal size and increased cell packing density in a variety of limbic system structures including the hippocampus, a change consistent with curtailment of normal development. Based on these observations in the hippocampus, a series of quantitative receptor autoradiographic studies were undertaken to determine the density and distribution of eight types of neurotransmitter receptors from four neurotransmitter systems (GABAergic, serotoninergic [5-HT], cholinergic, and glutamatergic). Data from these single concentration ligand binding studies indicate that the GABAergic receptor system (³[H]-flunitrazepam labeled benzodiazepine binding sites and ³[H]-muscimol labeled GABA_A receptors) is significantly reduced in high binding regions, marking for the first time an abnormality in the GABA system in autism. In contrast, the density and distribution of the other six receptors studied (³[H]-8OH-DPAT labeled 5-HT_1A receptors, ³[H]-ketanserin labeled 5-HT₂ receptors, ³[H]-pirenzepine labled M1 receptors, ³[H]-hemicholinium labeled high affinity choline uptake sites, ³[H]-MK801 labeled NMDA receptors, and ³[H]-kainate labeled kainate receptors) in the hippocampus did not demonstrate any statistically significant differences in binding.     

Modulation of 5-HT1A receptor mediated response by fluoxetine in rat brain

Summary. Radioligand binding studies were done to investigate the effect of chronic administration of fluoxetine on 5-HT₁ receptor mediated response to adenylate cyclase (AC) in rat brain. Our studies revealed a significant decrease in the densities of 5-HT₁ and 5-HT_1A receptor sites in cortex and hippocampus of rat brain after chronic administration of fluoxetine (10 mg/Kg body wt.). However there was no significant change in the affinity of [³H]5-HT and [³H]DPAT for 5-HT₁ and 5-HT_1A receptor sites, respectively. However, in striatum, along with a significant (75%) downregulation of 5-HT₁ sites, the affinity of [³H]5-HT to these sites was increased, as revealed by decrease in Kd (0.50 ± 0.08 nM). Displacement studies showed that fluoxetine has higher affinity for 5-HT_1A receptors with a Ki value of 14.0 ± 2.8 nM, than 5-HT₁ sites. No significant change was observed in basal AC activity in any region after fluoxetine exposure. However, in cortex of experimental rats the 5-HT stimulated AC activity was significantly increased (16.03 ± 0.97 pmoles/mg protein; p < 0.01), when compared to 5-HT stimulated AC activity (12.98 ± 0.78 pmoles/mg protein) in control rats. The increase in 5-HT stimulated AC activity in cortex may be due to the significant downregulation of 5-HT_1A sites in cortex after fluoxetine exposure as these sites are negatively coupled to AC. The observed significant decrease in 5-HT₁ sites with concomitant increase in 5-HT stimulated AC activity, after fluoxetine treatment, suggests that fluoxetine, which has high affinity for these sites, acts by modulating the 5-HT_1A receptor mediated response in brain. Accepted August 25, 1999     

Autoradiographic comparison of D1-specific binding of [H]SCH39166 and SCH23390 in the primate cerebral cortex

Quantitative autoradiography was used to compare the binding of the novel dopamine D₁ receptor antagonist, [³H]SCH39166, with that of the widely used radioligand, [³H]SCH23390 (in the presence of ritanserin), in the primate cerebral cortex. Specific binding of both radioligands, determined using SCH23390 or cis-flupentixol as displacing agents, had very similar densities and distributions throughout the cortex. However, the specific binding of [³H]SCH39166 obtained with SCH39166 as a blank was significantly higher than that obtained using SCH23390 or cis-flupentixol as displacing agents in some layers of motor, somatosensory and occipital cortices. In addition, the non-specific binding of [³H]SCH39156 obtained in the presence of an excess of SCH23390 of cis-flupentixol displayed a complex laminar pattern very different from that of the specific binding. These observations suggest that [³H]SCH39166 may have a high affinity to more than the D₁ receptor subtype bound by SCH23390 or cis-flupentixol. Also, these additional sites are likely to be different from 5-HT₂ or 5-HT_1C receptors since the latter sites were not displaced by 1 μM SCH23390.     

Feedback Stimulation of Somatodendritic Serotonin Release: A 5-HT3 Receptor-Mediated Effect in the Raphe Nuclei of the Rat

Slices from rat midbrain containing the raphe nuclei and from hippocampus were prepared, loaded with [³H]5-HT and superfused and the resting and the electrically stimulated [³H]5-HT release was measured. The 5-HT₃ receptor agonist 2-methyl-5-HT (1 to 10 μmol/l) increased the resting tritium outflow in superfused raphe nuclei slices, EC₅₀ 5.3 μmol/l. The 2-methyl-5-HT-induced increase of tritium outflow was an external Ca²⁺-independent process and was not altered by reserpine pretreatment but it was reversed by addition of the 5-HT uptake inhibitor fluoxetine (1 μmol/l). The 5-HT₃ receptor antagonists ondansetron and GYKI-46 903 (1 μmol/l) did not antagonize the stimulatory effect of 2-methyl-5-HT on resting tritium outflow. 2-Methyl-5-HT in lower concentration increased the electrically induced tritium overflow from raphe nuclei slices (EC₅₀ 0.56 μmol/l) and also from hippocampal slices preloaded with [³H]5-HT. These effects were reversed by 1 μmol/l of ondansetron and GYKI-46903. The 5-HT₃ receptor antagonists (1 μmol/l) were without effects on depolarization-evoked [³H]5-HT release at 2 Hz stimulation, when 10 Hz stimulation was used, ondansetron and GYKI-46 903 reduced the tritium overflow from raphe nuclei slices. These data indicate that 5-HT₃ receptors positively alter depolarization-induced somatodendritic 5-HT release in the raphe nuclei. They also show that 2-methyl-5-HT is able to evoke 5-HT release not only from vesicles but also from cytoplasmic stores via a transporter-dependent exchange process.     

Autoradiographic localization of 5-HT1A receptors in the post-mortem human brain using [H]WAY-100635 and [C]WAY-100635

The distribution of 5-HT_1A receptors was examined in the post-mortem human brain using whole hemisphere autoradiography and the selective 5-HT_1A receptor antagonist [³H]WAY-100635 ([O-methyl-³H]-N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide trihydrochloride). The autoradiograms showed very dense binding to hippocampus, raphe nuclei and neocortex. The labeling in neocortex was slightly lower than in the hippocampus and was mainly at superficial layers, although a faintly labeled band could be seen in deeper neocortical layers. Other regions, such as the amygdala, septum and claustrum, showed low densities of [³H]WAY-100635 binding, reflecting low densities of 5-HT_1A receptors. The labeling was very low in basal ganglia, such as nucleus caudatus and putamen, in cerebellum or in structures of the brain stem except in the raphe nuclei. The labeling of human 5-HT_1A receptors with [³H]WAY-100635 was antagonized by the addition of the 5-HT_1A receptor ligands, 5-HT, buspirone, pindolol or 8-OH-DPAT (10 μM), leaving a very low background of non-specific binding. Saturation analysis of semiquantitative data from several human regions indicated that [³H]WAY-100635 has a K_d of approximately 2.5 nM. The selective labeling of 5-HT_1A receptors with [³H]WAY-100635 clearly show that this compound is useful for further studies of the human 5-HT_1A receptor subtype in vitro. [¹¹C]WAY-100635 is used for the characterization of 5-HT_1A receptors with positron emission tomography (PET). WAY-100635 was also radiolabeled with the short-lived positron-emitting radionuclide carbon-11 (t_1/2=20 min) and used for in vitro autoradiography on human whole hemisphere cryosections. [¹¹C]WAY-100635 gave images qualitatively similar to those of [³H]WAY-100635, although with a lower resolution. Thus, the hippocampal formation was densely labeled, with lower density in the neocortex. Buspirone, pindolol or 8-OH-DPAT (10 μM), blocked all binding of [¹¹C]WAY-100635. The in vitro autoradiography of the distribution of 5-HT_1A receptors obtained with radiolabeled WAY-100635 provide detailed qualitative and quantitative information on the distribution of 5-HT_1A-receptors in the human brain. Moreover, the studies give reference information for the interpretation of previous initial results at much lower resolution in humans with PET and [¹¹C]WAY-100635. These data provide a strong basis for expecting [¹¹C]WAY-100635 to behave as a highly selective radioligand in vivo.     

Autoradiographic mapping of 5-HT1B and 5-HT1D receptors in the post mortem human brain using [H]GR 125743

The distribution of 5-HT_1B and 5-HT_1D receptors in the human post mortem brain was examined using whole hemisphere autoradiography and the radioligand [³H]GR 125743. [³H]GR 125743 binding was highest in the substantia nigra and the globus pallidus. Lower levels were detected in the striatum, with the highest densities in the ventromedial parts. In the amygdala, the hippocampus, the septal region and the hypothalamus, lower [³H]GR 125743 binding was observed, reflecting low densities of 5-HT_1B/1D receptors. In the cerebral cortex, binding was similar in most regions, although restricted parts of the medial occipital cortex were markedly more densely labeled. Binding densities were very low in the cerebellar cortex and in the thalamus. Two methods were used to distinguish between the two receptor subtypes, the first using ketanserin to block 5-HT_1D receptors and the second using SB 224289 to inhibit 5-HT_1B receptor binding. The autoradiograms indicated that in the human brain, the 5-HT_1B receptor is much more abundant than the 5-HT_1D receptor, which seemed to occur only in low amounts mainly in the ventral pallidum. Although [³H]GR 125743 is a suitable radioligand to examine the distribution of 5-HT_1B receptors in the human brain in vitro, the selectivities of ketanserin and SB 224289 are not sufficiently high to give definite evidence for the occurrence of the 5-HT_1D receptor in the human brain.     

Modulation of serotonin binding sites in the brain of the Djungarian hamster,Phodopus sungorus,during adaptation to a short photoperiod

Summary During the physiological adaptation of the Djungarian hamster,Phodopus sungorus, to a short photoperiod in autumn the modulation of specific serotonin (5-HT) binding sites of synaptic membranes was investigated in two brain regions, i.e. cerebral cortex and basal brain (CNS without cerebral cortex, cerebellum, pineal gland, and spinal cord). The radioligands [³H]5-HT and [³H]ketanserin were used to characterize total 5-HT₁ and 5-HT₂ binding sites, respectively. An increase of 5-HT₁ and 5-HT₂ binding sites was observed in both brain regions within 14 days after reduction of the photoperiod from a 1410 h light/dark (l/d) cycle to an 816 h l/d cycle. The increase was still present after 56 days of the short photoperiod. Binding kinetics assayed after 4 days of the short photoperiod show that maximal specific binding of [³H]5-HT and [³H]ketanserin was increased, while dissociation constants (K_D) were not changed. The membrane anisotropy of synaptic membranes, measured by fluorescence polarization, was reduced transiently during the early part of the adaptation. Neither the phospholipids nor the mole ratio of cholesterol to phospholipids were significantly affected by adaptation to short photoperiod. The results suggest an important role of the central nervous 5-HT system in the physiological adaptation of the Djungarian hamster to a short photoperiod.     

Atypical in vitro and in vivo binding of [3H]S-14506 to brain 5-HT1A receptors

Summary The tritiated derivative of the potent 5-HT_1A receptor agonist S-14506 {1[2-(4-fluorobenzoylamino)ethyl]-4-(7-methoxynaphtyl)piperazine} was tested for its capacity to selectively label the serotonin 5-HT_1A receptors both in vitro in the rat and the mouse brain, and in vivo in the mouse. In vitro studies showed that the pharmacological profile and the distribution of [³H]S-14506 specific binding sites (Kd=0.15 nM) in different brain regions matched perfectly those of the prototypical 5-HT_1A receptor ligand [³H]8-OH-DPAT. However, in the three regions examined (hippocampus, septum, cerebral cortex), the density of [³H]S-14506 specific binding sites was significantly higher (+ 66–90%) than that found with [³H]8-OH-DPAT. Whereas the specific binding of [³H]8-OH-DPAT was markedly reduced by GTP and Gpp(NH)p and increased by Mn²⁺, that of [³H]S-14506 was essentially unaffected by these compounds. In addition, the alkylating agent N-ethylmaleimide was much less potent to inhibit the specific binding of [³H]S-14506 than that of [³H]8-OH-DPAT. Measurement of in vivo accumulation of tritium one hour after i.v. injection of [³H]S-14506 to mice revealed marked regional differences, with about 2.5 times more radioactivity in the hippocampus than in the cerebellum. Pretreatment with 5-HT_1A receptor ligands prevented tritium accumulation in the hippocampus but not in the cerebellum. Autoradiograms from brain sections of injected mice confirmed the specific in vivo labeling of 5-HT_1A receptors by [³H]S-14506, therefore suggesting further developments with derivatives of this molecule for positron emission tomography in vivo in man.     

No alterations in the 5-HT1A-mediated inhibition of forskolin-stimulated adenylate cyclase activity in the hippocampal membranes from rats chronically treated with lithium or antidepressants

Summary In order to determine the relevance of 5-HT_1A-related signal transduction in the mode of action of lithium and antidepressants, the effects of long-term treatment with these drugs on the 5-HT_1A-mediated inhibition of forskolin-stimulated adenylate cyclase activity were investigated in the rat hippocampal membranes. Chronic administration of antidepressants altered neither the [³H]8-hydroxy-2-(di-n-propylamino)tetralin ([³H]8-OH-DPAT) binding sites nor the inhibition of forskolin-stimulated adenylate cyclase activity by 5-HT. Long-term treatment with lithium did not affect the inhibitory effect of 5-HT on the forskolin-stimulated adenylate cyclase activity, either. Neither the stimulation by forskolin nor the inhibition by guanyl-5-ylimidodiphosphate (Gpp(NH)p) of adenylate cyclase activity was not influenced by lithium treatment, suggesting that lithium has no effects on the components of adenylate cyclase system distal to the 5-HT_1A receptors.These results indicate that the 5-HT_1A-mediated neural transmission has not such an important relevance in the mechanisms of action of lithium or antidepressants.     

Release of [3H]5-hydroxytryptamine from the intermediate area of rat thoracic spinal cord is modulated by presynaptic autoreceptors

Serotonin (5-HT) nerve terminals innervate sympathetic preganglionic neurons of the intermediolateral cell column (IML); however, neither the depolarization-induced release of 5-HT nor the presence of presynaptic modulatory autoreceptors have been directly studied in this system. We used in vitro superfusion of the microdissected intermediate area (including the intermediolateral cell column, intercalated nucleus, and central autonomic nucleus) of the rat thoracic spinal cord to measure basal and stimulated release of preloaded [³H]5-HT. Elevated K⁺ evoked a concentration- and Ca²⁺ dependent release of [³H]5-HT. Exogenous 5-HT and the 5-HT_1B agonist, CGS-12066B, both decreased the K⁺-stimulated release of [³H]5-HT. A 5-HT_1B antagonist (methiothepin) blocked the 5-HT- and the CGS-12066B-induced inhibition of K⁺-evoked release of [³H]5-HT. A 5-HT_1A antagonist (NAN-190) did not alter the inhibitory actions of exogenous 5-HT. Moreover, a 5-HT_1A agonist (8-OH-DPAT), a 5-HT_2A/2C agonist [(+/-)-DOI hydrochloride], and a 5-HT₃ agonist (2-methyl-5-HT) did not alter the K⁺ evoked release of [³H]5-HT. These data demonstrate that 5-HT is released from the intermediate area of the rat thoracic spinal cord. The 5-HT receptor subtype involved in the inhibition of the evoked release of [³H]5-HT is of the 5-HT_1B subtype. These findings may help clarify the complex role of 5-HT in spinal regulation of the sympathetic nervous system. © 1994 Wiley-Liss, Inc

1 This article is US Government work and, as such, is in the public domain in the United States of America.

     

Characterization of 5-hydroxytryptamine binding sites in the plasma membrane of pig blood platelets

Summary Plasma membranes were isolated from pig platelets after glycerol facilitated lysis by sucrose density gradient centrifugation. The purity of the membrane fraction was followed by electron microscopy, gel electrophoresis and analysis of acid phosphatase (EC 3.1.3.2) and phosphodiesterases (EC 3.1.4.1). (³H)5-Hydroxytryptamine ([³H]5-HT) was bound to two saturable binding sites of the membranes. The K_D value for the high affinity sites was 0.85 nM and for the low affinity sites 0.48M. With the exception of tryptamines little or no (³H)5-HT was displaced by serotonin antagonists and uptake inhibitors suggesting another type of binding than that of 5-HT₁. Apparently, enhancement of binding in the presence of Na⁺ was due to stimulation of an uptake process. Binding of (³H)ketanserin and (³H)LSD to pig platelet membranes showed the characteristics of 5-HT₂ binding sites previously identified in rat brain. Since ketanserin inhibited 5-HT induced aggregation of pig platelets (IC₅₀=14.2 nM), the ketanserin binding sites can be classified as 5-HT₂ receptors. The functional properties of these binding sites and their density in pig platelets as compared with brain membranes may motivate studies on 5-HT₂ receptors in pig platelets as models for those in nerve endings.